8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 6, 2021

INVITAE CORPORATION

(Exact name of registrant as specified in its charter)

Delaware	001-36847	27-1701898
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

1400 16th Street, San Francisco, California	94103
(Address of principal executive offices)	(Zip Code)

(415) 374-7782

(Registrant’s telephone number,

including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	NVTA	The New York Stock Exchange LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.02 Unregistered Sales of Equity Securities.

Pursuant to that certain Agreement and Plan of Merger (the “Merger Agreement”), dated as of September 6, 2021, among Invitae Corporation (the “Company”), Cayman Merger Sub A Inc., a Delaware corporation and a wholly-owned subsidiary of the Company (“Merger Sub A”), Cayman Merger Sub B LLC, a Delaware limited liability company and a wholly-owned subsidiary of the Company (“Merger Sub B”), Ciitizen Corporation, a Delaware corporation (“Ciitizen”), and Fortis Advisors LLC, solely in its capacity as the representative, exclusive agent and attorney-in-fact of the holders (the acquisition transaction contemplated by the Merger Agreement, the “Ciitizen Transaction”), the Company will issue approximately 7,070,000 shares of its common stock, $0.0001 par value per share (“Common Stock”), on the closing date of the Ciitizen Transaction, in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933 (the “Securities Act”). The Company is relying on this exemption from registration based in part on representations that will be made by stockholders of Ciitizen receiving shares of Common Stock in the Ciitizen Transaction.

In addition, on July 19, 2021, the Company issued 988,751 shares of Common Stock, which included 169,330 shares subject to a 12-month holdback and 461,809 shares of deferred stock consideration, pursuant to that certain Membership Interest Purchase Agreement (the “Purchase Agreement”), dated July 19 2021, among the Company, Kamal Gogineni and Rakesh Patel (together, the “Sellers”), and Kamal Gogineni, as Sellers’ representative, pursuant to which the Company acquired 100% of the membership interests of Medneon LLC, a Delaware limited liability company (“Medneon” and such transaction, the “Medneon Transaction”). The shares of Common Stock issued in the Medneon Transaction were issued in reliance upon the exemption from registration provided by Section 4(a)(2) of the of the Securities Act. The Company relied on this exemption from registration based in part on representations that were made by the Sellers.

Item 7.01 Regulation FD Disclosure.

On September 7, 2021, the Company issued a press release announcing the Ciitizen Transaction. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. In addition, on September 7, 2021, the Company distributed an investor presentation which is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

The information in Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

Item 8.01 Other Events.

Merger Agreement

On September 6, 2021, the Company, Merger Sub A, Merger Sub B, Ciitizen, and Fortis Advisors LLC entered into the Merger Agreement pursuant to which, among other things and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, the Company will acquire 100% of the fully diluted equity of Ciitizen. Pursuant to the Merger Agreement, Merger Sub A will merge with and into Ciitizen, with Ciitizen surviving the merger and continuing as a wholly-owned subsidiary of the Company (the “Reverse Merger”) and, promptly following the Reverse Merger, Ciitizen will merge with and into Merger Sub B, with Merger Sub B surviving the merger and continuing as a wholly-owned subsidiary of the Company (the “Forward Merger” and, together with the Reverse Merger, the “Merger”). The Merger is intended to qualify for federal income tax purposes as a tax-free reorganization under the provisions of Section 368(a) of the Internal Revenue Code of 1986, as amended.

The aggregate consideration for the Merger will be approximately $325 million (subject to adjustment), consisting of approximately $125 million in cash and approximately 7,070,000 shares of Common Stock (based upon a trailing average closing price prior to the date of the Merger Agreement). The consideration to be paid on the closing date is subject to closing-related adjustments based on Ciitizen’s cash, debt, net working capital and other expenses at the closing of the Merger. Subject to the terms and conditions of the Merger Agreement, at the closing of the Merger, (i) each outstanding share of Ciitizen capital stock will be converted into the right to receive the number of shares of

2

Common Stock (for consenting accredited stockholders of Ciitizen) and a cash payment (for all stockholders of Ciitizen) as specified in the Merger Agreement, (ii) each outstanding and unexercised Ciitizen stock option will be converted into the right to receive a cash payment as specified in the Merger Agreement, and (iii) each outstanding and unexercised Ciitizen warrant will be converted into the right to receive a cash payment as specified in the Merger Agreement. No fractional shares will be issued in connection with the Merger and any shares issuable to a single holder on a particular date will be aggregated and rounded up to the nearest whole number.

Closing Conditions; Closing Date

The obligations of the parties to consummate the Merger are subject to the satisfaction or waiver of various conditions set forth in the Merger Agreement, including, but not limited to (i) the accuracy of the representations and warranties of each party contained in the Merger Agreement (subject to certain materiality qualifications), (ii) each party’s compliance with or performance of the covenants and agreements in the Merger Agreement in all material respects, and (iii) execution of employment and non-competition agreements with the Company by certain employees of Ciitizen. The Merger is expected to close within the month of September 2021, subject to customary closing conditions.

Representations and Warranties; Covenants

The Merger Agreement contains customary representations and warranties by the Company and Ciitizen. The Merger Agreement also contains customary covenants and agreements, including with respect to the operations of the business of Ciitizen between signing and closing. The Merger Agreement restricts Ciitizen’s ability to participate in any discussions or negotiations with any third party with respect to any alternative transaction.

Termination

The Merger Agreement contains termination rights for the Company and Ciitizen, including if the Merger is not consummated within 60 days after the date of the Merger Agreement, which may be extended by the mutual consent of the Company and Ciitizen.

Registration Rights Agreement

In connection with the Ciitizen Transaction, the Company will enter into a Registration Rights Agreement with certain stockholders of Ciitizen (the “Registration Rights Agreement”), pursuant to which the Company will register for resale on Form S-3 the shares of Common Stock to be issued in the Merger. The Registration Rights Agreement provides that such registration rights will expire at such time as such shares of Common Stock have been disposed of pursuant to the resale registration statement or pursuant to Rule 144, or as to any holder when all of such holder’s shares may be sold pursuant to Rule 144 without limitation as to manner of sale restrictions or volume limitation.

RSU Agreements

In connection with the Ciitizen Transaction, the Company will grant restricted stock units for an aggregate of up to approximately 8,125,000 shares of Common Stock (the “Inducement Awards”), or approximately $225 million in Inducement Awards (based upon a trailing average closing price prior to the date of the Merger Agreement), to certain employees of Ciitizen in connection with and as an inducement to their post-closing employment by the Company (each, a “Continuing Employee”), pursuant to time-based restricted stock unit award agreements (the “RSU Agreements”). Under the RSU Agreements, the Company will issue shares of Common Stock to the Continuing Employees at such times, and upon such conditions (including with respect to the vesting of such shares), as are set forth therein.

The Inducement Awards will be granted as inducement awards in compliance with New York Stock Exchange Rule 303A.08 and pursuant to a pool solely for inducement awards established under the Invitae Corporation 2015 Stock Incentive Plan, which pool is being amended to increase the available shares of Common Stock in connection with the Ciitizen Transaction.

3

Forward-Looking Statements

Certain statements either contained in or incorporated by reference into this Current Report on Form 8-K, other than purely historical information, are “forward-looking statements.” All statements, other than statements of historical facts, included in or incorporated by reference into this Current Report on Form 8-K regarding future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the structure, timing and expected completion of the proposed Ciitizen Transaction. The Company may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, risks and uncertainties associated with the ability to consummate the proposed Ciitizen Transaction. The Company disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Press Release issued by Invitae Corporation, dated September 7, 2021.
99.2	Investor Presentation, dated September 7, 2021.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

4

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 7, 2021

INVITAE CORPORATION
By:	/s/ Yafei (Roxi) Wen

Name:	Yafei (Roxi) Wen
Title:	Chief Financial Officer

EX-99.1

Exhibit 99.1

Invitae to Acquire Ciitizen to Strengthen its Patient-Consented Health Data Platform to Improve Personal Outcomes and Global Research

— Ciitizen platform will empower patients to securely collect, organize and benefit from their full range of health data —

— Combination to bring together the power of genomic and clinical information within a new kind of patient data platform to improve healthcare decision making at personal and systemwide levels —

— Hosting Conference Call and Webcast for investors today at 8:30 a.m. ET / 5:30 a.m. PT —

SAN FRANCISCO, September 7, 2021 — Invitae (NYSE: NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Ciitizen, a patient-centric consumer health tech company. Backed by a16z, Section 32 and Verily, Ciitizen is working to build a global platform to help patients collect, organize, store and share their medical records digitally. The acquisition would enhance Invitae’s platform by providing patients an easy-to-use, centralized hub for their genomic and clinical information, which together comprise a powerful dataset with the potential to drive research and improve healthcare decision making.

“Invitae is relentlessly pursuing a day when genetics is used routinely to improve healthcare for billions of people around the globe. We believe combining Ciitizen’s state-of-the-art, transparent and patient-consented platform with our technologies and services will accelerate our evolution into a genome information company that informs healthcare throughout one’s life. This would give us the ability to engage patients, create an innovative patient-centered data ecosystem and deliver better outcomes for everyone. Invitae views the acquisition of Ciitizen as an important part of its strategy to be the industry leader across the genetic testing, software and health information technology spaces,” said Sean George, Ph.D., co-founder and CEO of Invitae.

“Ciitizen has already helped patients take ownership of their medical records to optimize therapy for themselves and contribute their data towards a variety of goals, including research on rare diseases,” said Anil Sethi, CEO and founder of Ciitizen. “Patients leave a breadcrumb trail of records behind them, and we believe access to this real-world data is key to personalized therapeutics in the future. The combination of lifelong health history together with Invitae’s world-class genetic and data services would enable a digital ecosystem of personalized services for each patient. Democratization of patient-consented data is expected to improve outcomes by providing access to third-parties for whom the patient has granted consent. Unlike many health data companies, we operate on the premise that it’s the patient’s data, not ours.”

Dr. George continued, “Genomics is currently a laboratory testing-based industry, but in the future it will look very much like an information industry. Developing an open-ended patient-centric platform of genomic, clinical and

1

reported outcomes creates a thriving and purposeful network that truly advances healthcare. Patient control is the big differentiator at Ciitizen and at Invitae; and we believe combining forces is the right strategy for our business going forward.”

Empowering patients to combine their genomic and clinical information to improve clinical care

Invitae is working to aggregate results from the world’s genetic tests into a single, easy-to-use service that makes genetic information accessible to all who can benefit from it - always with patient consent. Over the past five years, Invitae has completed 13 acquisitions that have expanded its testing menu, lowered the cost of its tests, improved its customer experience and enhanced its ability to attract partners. Invitae raised more than $1.4 billion since the beginning of 2021, in part to identify and acquire key assets that bring the company closer to delivering on its vision.

The addition of Ciitizen is expected to empower Invitae to more quickly extend its platform, adding a complementary patient service that streamlines the process of collecting and organizing health information from any source and uses machine learning to transform the unstructured (and largely untapped) health information to enable better care decisions, find clinical trials, and power research using real-world evidence. In addition, as the use of Invitae testing and the Ciitizen service expands, third-party access to consented genomic and other clinical data can be democratized to power a variety of applications that can enhance Invitae’s business and growth strategy.

Transaction Terms

Under the terms of the agreement, Invitae will acquire Ciitizen for approximately $325 million (subject to adjustment), consisting of (i) approximately $125 million in cash and (ii) approximately 7,070,000 shares of Invitae common stock (based upon a trailing average closing price prior to the agreement date). Invitae will also issue approximately $225 million in restricted stock units (RSUs) to new employees who join Invitae in connection with its acquisition of Ciitizen. These RSUs will be granted under Invitae’s 2015 Stock Incentive Plan, which is being amended and restated to increase a pool of shares of Invitae common stock thereunder which is used exclusively for the grant of inducement awards in compliance with New York Stock Exchange Rule 303A.08 (“Rule 303A.08”). These RSUs have been approved by the Invitae Board of Directors and will be made as an inducement material to each employee entering into employment with Invitae in reliance on the employment inducement exemption under Rule 303A.08. These RSUs will cover up to a total of approximately 8,125,000 shares of Invitae common stock (based upon a trailing average closing price prior to the agreement date) and will vest in tranches of one-third upon each of the first, second and third anniversaries of the date of grant, subject to acceleration in the event of a termination without cause by Invitae or a termination with good reason by a recipient. A total of approximately 99 recipients will receive these RSUs, and Anil Sethi, the CEO and founder of Ciitizen, will receive RSUs with respect to approximately 2,011,000 shares of Invitae common stock.

The transaction, which has been unanimously approved by the Boards of Directors of both companies, is expected to close this month.

Conference Call and Webcast today at 8:30 a.m. ET / 5:30 a.m. PT

Management will host a conference call and webcast today at 8:30 a.m. ET / 5:30 a.m. PT to discuss the transaction. To register for the conference call, please use the link below. Upon registering, each participant will be provided with call details and a registrant ID.

2

Online registration: http://www.directeventreg.com/registration/event/6232019

The live webcast of the call and slide deck may be accessed here or by visiting the investors section of the company’s website at ir.invitae.com. A replay of the webcast and conference call will be available shortly after the conclusion of the call and will be archived on the company’s website.

About Invitae

Invitae Corporation (NYSE: NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae’s goal is to aggregate the world’s genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company’s website at invitae.com.

About Ciitizen

Ciitizen is a patient-centric consumer health technology platform that enables patients to collect, store and share their medical records in a single location. Ciitizen developed proprietary machine learning and AI technologies to abstract critical information from unstructured health records to advance the understanding of diseases, match patients with potentially life-saving clinical trials, and enable better care decisions. Ciitizen also provides valuable big data analytics and data quality technologies to the network of Health Information Exchanges (HIEs) to produce research-ready, regulatory-grade data within minutes, instead of hours or days, and ensure HIEs can comply with the Information Blocking regulations.

For more information, visit Ciitizen.com or follow @Ciitizencorp.

Ciitizen, the Ciitizen logo and Ciitizen Corp are trademarks and service marks of Ciitizen Corp. You are not permitted to use the Marks without prior written consent of Ciitizen Corp.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected benefits and advantages of the proposed acquisition, including future products and services and customers served, benefits to patients, synergies, opportunities, product attributes and offerings, and financial and other effects, the transaction structure, and the expected timing of completion of the proposed acquisition; statements regarding Invitae’s belief that the acquisition will accelerate the evolution of its business and the nature and benefits of any such evolution; and Invitae’s beliefs regarding its business and growth strategy and its views with respect to the future of the industry. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to: the ability of the parties to close the transaction, including obtaining any required regulatory approvals; the failure to realize the anticipated benefits from the proposed acquisition on a timely basis or at all; the ability of Invitae to execute its business strategy; the ability of Invitae to develop a health data platform and the benefits thereof; the risk that the anticipated benefits from the proposed acquisition cannot be realized in full or at all or may take longer to realize than expected; risks related to integration and employee retention; the amount and nature of competition; and the other

3

risks set forth in Invitae’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021. These forward-looking statements speak only as of the date hereof, and Invitae disclaims any obligation to update these forward-looking statements.

NOTE: Invitae and the Invitae logo are trademarks of Invitae Corporation. All other trademarks and service marks are the property of their respective owners.

Contact for Invitae:

ir@invitae.com

(628) 213-3369

Media Contact for Ciitizen:

ciitizen@10fold.com

4

EX-99.2

Acquisition and platform update 09 | 07 | 21 From genetics, health + Exhibit 99.2

Safe harbor statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company’s beliefs regarding the potential benefits of its pending acquisition of Ciitizen; the expected transaction terms; the company’s beliefs regarding its business and business strategy; and the benefits and importance of the company’s acquisitions and collaborations. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the closing of the pending acquisition of Ciitizen; the ability of the company to achieve the expected benefits of the acquisition; the impact of COVID-19 on the company, and the effectiveness of the efforts it has taken or may take in the future in response thereto; the company's ability to continue to grow its business, including internationally; the ability to maintain important customer relationships; the company’s ability to compete; the company's failure to manage growth effectively; the company's need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; the risk that the company may not obtain or maintain sufficient levels of reimbursement for its tests; the company’s ability to obtain regulatory approval for its tests; the company's failure to successfully integrate or fully realize the anticipated benefits of acquired businesses; risks associated with litigation; the company's ability to use rapidly changing genetic data to interpret test results accurately and consistently; the applicability of clinical research results to actual outcomes; the success of collaborations; security breaches, loss of data and other disruptions; laws and regulations applicable to the company's business; and the other risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2021. These forward- looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.

Single greatest shift in medicine and healthcare “Modern” medicine Chemotherapy standard of care Newborn diagnosis after birth Symptom-based, universally applied Universal testing for all Risk information = effective prevention Earliest detection – disease eradication Personalized therapy and biomarker driven monitoring Gene informed healthcare throughout life

Invitae’s mission and core data tenets Patients own their health data Health data is more valuable when shared

A patient-mediated platform that allows patients to collect and store their medical records, and turns documents into usable, computable and relevant longitudinal data that can be shared with whomever they consent A patient-mediated platform for data sharing

Founder of Gliimpse, acquired by Apple in 2016 Data with a purpose - Ciitizen’s founding story Anil Sethi Ciitizen Muse - Tania Founded Ciitizen following the death of his sister, Tania, who battled metastatic breast cancer

Challenges within the current system Fragmented & non-standard data “Dark data”, limited by FHIR Onerous to access my data Perceived risk to privacy

How it works Onboard to Ciitizen Consent to share data Use patient’s HIPAA right of access-to-access raw records Ciitizen obtains all, unstructured records Medical records and images uploaded to patient’s account Step 1: Collect all medical documents

How it works (con’t) AI/machine learning extraction Defined data elements Human assisted quality review Patients own their data and can easily share records and images with any provider or person Step 2: Convert documents into useful data

One Company. One Patient. All patients FERTILITY & PERINATAL HEALTH ASSISTED REPRO PRENATAL TESTING NEONATAL TESTING PEDIATRIC TESTING CARRIER SCREENING ADULT DIAGNOSTIC THERAPY GUIDANCE PHARMACOGENOMICS RISK ASSESSMENT MRD/RECURRENCE MONITORING Age 18–40 Age 0–17 Age 41–65 Age 65+

Patients own and control their data Consent & preferences Security Privacy Transparency of usage Usefulness to the patient and society Accuracy Trust is the Foundation of our Strategy

Precision Medicine Marketplace Patient-centered data will drive the molecular medicine era* Clinical Commercial Research Patient-Centered Data Platform + Digital Capabilities Conception / Women’s Health Genetic Risk / Screening Oncology Treatment / Monitoring Newborn / Rare Disease Retail Healthcare Govt Payors Private Insurance Actuarial Discovery Trials Patient Community Genomic Testing Platform * Assuming completion of acquisition

Data/platform and information flow* Inputs/ Patient Data Personal Digital Health Wallet Outputs/ Patient Benefits Genomic profiles Historical procedures Family history/lifestyle EMR sources Biometric/wearables Patient surveys Imaging records Pharmacy Decision support Trial matching Clinical trial access Real-world data Outcomes data Advocacy Reimbursement support * Assuming completion of acquisition

Telemedicine Networks Pharmacy/Retail Health Payor Ecosystem Healthcare Provider Networks Biopharma/Testing Opening up to a variety of partnerships and ecosystem players Patient Advocacy Groups

Upfront Value Employee Retention Summary transaction terms* Summary terms Cash $125M(1) Shares of Invitae common stock $7.07M(2) Total Upfront Cash and Shares $325M RSUs for Continuing Employees $225M(3) Notes: * Subject to closing (1)Subject to adjustment for debt, working capital and transaction expenses (2)Consideration paid in shares calculated based on a trailing closing average price (3)RSUs vest over time

Provide genetic information services that inform healthcare throughout life Share genetics on a global scale to diagnose more patients correctly, earlier, and bring therapies to market faster Build partnerships with industry peers to increase utilization of genetic testing Make acquisitions that expand test menu content and services to open new markets Make genetic testing more affordable and more accessible GENOME NETWORK GENETIC TESTING GENOME MANAGEMENT Bringing genetics into mainstream medicine

Q&A

XML

Document and Entity Information	Sep. 06, 2021
Cover [Abstract]
Entity Registrant Name	Invitae Corp
Amendment Flag	false
Entity Central Index Key	0001501134
Document Type	8-K
Document Period End Date	Sep. 06, 2021
Entity Incorporation State Country Code	DE
Entity File Number	001-36847
Entity Tax Identification Number	27-1701898
Entity Address, Address Line One	1400 16th Street
Entity Address, City or Town	San Francisco
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94103
City Area Code	(415)
Local Phone Number	374-7782
Written Communications	false
Soliciting Material	false
Pre Commencement Tender Offer	false
Pre Commencement Issuer Tender Offer	false
Security 12b Title	Common Stock, $0.0001 par value per share
Trading Symbol	NVTA
Security Exchange Name	NYSE
Entity Emerging Growth Company	false